| Abstract: |
Overexpressing or amplified human epidermal growth factor receptor 2 (HER2) is found in 20% to 25% of breast cancers, which is associated with aggressive biology and worse overall survival. HER2-targeted therapies have dramatically improved the clinical outcomes of patients with HER2-positive breast cancer, both in neoadjuvant/adjuvant and in metastatic settings. For metastatic breast cancer (MBC), HER2 targeted drugs approved by the Food and Drug Administration include trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). This article reviews the optimal management of HER2-targeted therapies and describes emerging novel therapies in the treatment of HER2-positive MBC. |
